Daniel Morillo
30 Papers
11 Citations
Daniel Morillo is an academic researcher. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 4, co-authored 9 publications.
Chat about Author
Papers
First results from the RedirecTT-1 study with teclistamab (tec) + talquetamab (tal) simultaneously targeting BCMA and GPRC5D in patients (pts) with relapsed/refractory multiple myeloma (RRMM).
Yael C Cohen,Daniel Morillo,Moshe E. Gatt,Michael Sebag,Ki-Hyun Kim,Chang-Ki Min,Albert Oriol,Enrique M. Ocio,Sung-Soo Yoon,Maria-Victoria Mateos,Michael Chu,Paula Rodriguez-Otero,Irit Avivi,Yue Guo,Maria Krevvata,Melissa Beelen,Jill M. Vanak,Arnob Banerjee,Hila Magen +18 more
TL;DR: The first results from the phase 1b RedirecTT-1 trial (NCT04586426) in pts with RRMM were reported in this paper , where the first combination study of a BCMA-and GPRC5D-targeted bispecific antibody, tec + tal, was presented.
50
Talquetamab (tal) + daratumumab (dara) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Updated TRIMM-2 results.
Bhagirathbhai Dholaria,Katja Weisel,Maria-Victoria Mateos,Hartmut Goldschmidt,Thomas R. Martin,Daniel Morillo,Donna E. Reece,Paula Rodriguez-Otero,Manisha Bhutani,Anita D'Souza,Albert Oriol,Laura Rosiñol,Nizar J. Bahlis,Kalpana Bakshi,Lijuan Kang,Lien Vandenberk,Marie-Anne Damiette Smit,Ralph Wäsch,N. W. C. J. van de Donk,Ajai Chari +19 more
TL;DR: The authors showed that combining immunomodulatory effects of tal + dara may lead to synergistic efficacy and increased CD38+/CD8+ T cells and proinflammatory cytokines.
36
A novel, immunotherapy-based approach for the treatment of relapsed/refractory multiple myeloma (RRMM): Updated phase 1b results for daratumumab in combination with teclistamab (a BCMA x CD3 bispecific antibody).
Paula Rodriguez-Otero,Anita D'Souza,Donna E. Reece,N. W. C. J. van de Donk,Ajai Chari,Amrita Krishnan,Thomas R. Martin,Maria-Victoria Mateos,Daniel Morillo,David D. Hurd,Laura Rosiñol,Anna Sureda Balari,Ralph Wäsch,Deeksha Vishwamitra,S. X. Wang Lin,Thomas J. Prior,Lien Vandenberk,Marie-Anne Damiette Smit,A. Oriol Rocafiguera,Bhagirathbhai Dholaria +19 more
TL;DR: Upregulation of CD38+/CD8+ T cells and proinflammatory cytokines was observed with tec + dara, supporting potential synergy of the combination in pts with prior anti-CD38 exposure and providing a novel immunotherapy approach for the treatment of RRMM.
21
Phase I Study of the PTEFb Inhibitor BAY 1251152 in Patients with Acute Myelogenous Leukemia
Michael Byrne,Mark G. Frattini,Oliver G. Ottmann,Ioannis Mantzaris,Martin Wermke,Daniel J. Lee,Daniel Morillo,Arne Scholz,Stuart Ince,Ray Valencia,Fabricio Souza,Raul Cordoba +11 more
TL;DR: Interestingly, pharmacodynamic assessment of MYC, MCL-1 and PCNA mRNA in whole blood indicated that BAY treatment led to significant, but short-lived, reductions; however, no objective responses were observed, with only modest reductions in bone marrow blasts in some patients.
18
S183: novel combination immunotherapy for the treatment of relapsed/refractory multiple myeloma: updated phase 1b results for talquetamab (a gprc5d x cd3 bispecific antibody) in combination with daratumumab
N. W. van de Donk,N. Bahlis,M.V. Mateos,Katja Weisel,Bhagirathbhai Dholaria,Alfred L. Garfall,Hartmut Goldschmidt,Thomas R. Martin,Daniel Morillo,Donna E. Reece,David D. Hurd,Paula Rodriguez-Otero,Manisha Bhutani,A. D’Souza,Albert Oriol,Ehssan Sharif Askari,J. San-Miguel,K. Martin Kortüm,Deeksha Vishwamitra,S. Xin Wang Lin,Thomas J. Prior,Lien Vandenberk,Marie-Anne Damiette Smit,Jenna D. Goldberg,Ralph Wäsch,Ajai Chari +25 more
TL;DR: The TRIMM-2 study as mentioned in this paper evaluated the combination of talquetamab and Daratumumab (dara) for the treatment of multiple myeloma (MM) using a randomized trial.
14